ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up

After two immunotherapies demonstrated their power against endometrial cancer, AstraZeneca now suggests that adding Merck-partnered Lynparza to its Imfinzi may offer another option.

The addition of Imfinzi and Lynparza on top of chemotherapy reduced the risk of disease progression or death by 45% in patients with newly diagnosed advanced or recurrent endometrial cancer. Adding just Imfinzi to chemo cut that same risk by 29%.